The goals of this research topic are to provide the current status of knowledge on b-cell senescence, some of the mechanisms by which it develops, its relevance in health and disease and its poten4al as a therapeu4c target. The present topic assembles two original research papers that explore the role of b-cell senescence in genera4onal transmission of metabolic dysfunc4on and the interac4on of senescence with altered nutrient sensing, another hallmark of aging. Addi4onally, two review papers and one perspec4ve consolidate the latest knowledge on b-cell senescence, mechanisms and markers, strategies to target this popula4on and propose an interes4ng perspec4ve of a poten4al role for senescence during pancrea4c islet development.Varghese SS et al. underscored how senescence does not only underlie aging and disease development, but also plays a vital role in embryogenesis, 4ssue regenera4on and repair of the pancreas. During embryologic development, growth and paIerning are partly dependent on p21 Cip1 -driven senescence and SASP promote macrophages chemotaxis to clear senescent cells and hence remodel 4ssues. Although this process is well-documented in the development of certain organs, it has not yet been described in pancrea4c islet development. However, it is known that high rates of b-cell replica4on occur during postnatal growth, which could increase risk of DNA damage. The laIer, in turn, is a well-known ini4ator of SASP which can recruit macrophages allowing only "fit" b-cells to persist and grow. This interes4ng hypothesis warrants further experimenta4on, given its important implica4ons for β-cell mass and its response to metabolic challenges in adulthood.Iwasaki K et al. explored the rela4onship between two known hallmarks of aging: altera4on in nutrient sensing through IGF1R, and senescence. Igf1r is a marker of aged β-cells, and the authors used two models of downregula4on of Igf1r signaling: Ames Dwarf mice, which have growth hormone deficiency and therefore decreased levels of Igf1, and an inducible b-cell specific Igf1r knock-down model. In both models, b-cell senescence markers were decreased. This was accompanied by improved glucose clearance, insulin secre4on and maintenance of cellular iden4ty, which persisted in the metabolic stress of high fat diet. These results suggest different levels of senescence regula4on which could derive in iden4fica4on of unique therapeu4c targets.In the review by Cha J et al., we provided an updated list of markers supported by literature to evaluate b-cell senescence. Although we expect this list to evolve with 4me, it is important to note that there is not one universal senescence marker that defines all senescent cells across 4ssues, aging and disease models, underscoring the complexity of this cellular state. We therefore provided a toolkit to assess β-cell senescence and recommend that several independent markers that iden4fy different features of senescence are tested in parallel to establish the presence of senescent b-cells. Importantly, we also highlighted that there is heterogeneity in β-cell senescence, and emerging evidence supports the existence of different subpopula4ons of senescent β-cells depending on the context and model. A robust iden4fica4on of these cell popula4ons and strategies to dis4nguish between them can then allow the development and evalua4on of interven4ons directed to clearing pathologic senescent β-cells. Several transgenic mouse models are discussed as are the most relevant pharmacological approaches directed at killing senescent cells (senoly4cs) or modula4ng their SASP (senomorphics).
Point out that while there might be benefits of dele4ng senescent cells, senoly4cs have the poten4al to reduce the mass of b-cells, which is already compromised in type 1 and type 2 diabetes. Addi4onally, the beneficial effects of senomorphics might be due to some off-target effect, such as decreasing blood glucose levels or local inflamma4on. Therefore, the authors suggest a third approach to target b-cells senescence through modulators of senescence which can act at different levels such as evading cell cycle arrest (mTOR, Nrf2, transcrip4on factor E2F1), microRNAs, splicing factors or dietary factors (probio4cs and faIy acids). As explained, polyunsaturated faIy acids (PUFAs), are par4cularly interes4ng candidates to regulate senescence as they have shown the capacity to aIenuate markers of immunosenescence, inflammaging and cytokine imbalance and are effec4ve in metabolically stressed pancrea4c b-cells.This issue also highlights the poten4al role of sex differences in b-cell senescence. Escalona R et al. evaluated the poten4al role of b-cell senescence as one of the mechanisms by which parental obesity increases the risk of offspring obesity, insulin resistance, diabetes and reproduc4ve disorders in a sex-dependent manner. Whereas they documented a clear increase in senescence (marked by increased Cdkn2a expression, encoding p16 ink4a , in b-cells) aaer 18 weeks of high fat diet, these changes did not persist in the male progeny, who s4ll showed metabolic impairment. Cha J et al. discussed what is currently known on sexual dimorphism and disease risk and speculate which aspects of sex might underlie differences in observed senescence rates and manifesta4ons between males and females. The most drama4c example of sexual dimorphism in b-cell senescence is in human and mouse carriers of a pathogenic variant S64F in the transcrip4on factor MAFA independent of sex hormones. Proposed mechanisms including sex-dependent responses to DNA damage and the role of genes encoded on sex chromosomes in repair mechanisms are described.In conclusion, b-cell senescence plays an important role in the development of diabetes and is a therapeu4c target with great poten4al to delay or halt progression of the metabolic diseases. We commend the authors for their work and their contribu4ons to this topical area in b-cell biology .